Predicting feasibility and characterizing performance of extended-release formulations using physiologically based pharmacokinetic modeling

Therapeutic Delivery

Volumn 3, Issue 9, 2012, Pages 1047-1059

  Brown, Jonathan ^a   Crison, John ^a   Timmins, Peter ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADINAZOLAM; ANTIVIRUS AGENT; ATECEGATRAN METOXIL; BMS 663068; CARBAMAZEPINE; DANOPREVIR; GISADENAFIL; METFORMIN; METOPROLOL; UNCLASSIFIED DRUG; ZOLPIDEM;

AREA UNDER THE CURVE; COLON ABSORPTION; COMPUTER MODEL; COMPUTER PROGRAM; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG METABOLISM; DRUG RELEASE; DRUG RESEARCH; DRUG TRANSPORT; EXPERIMENTAL MODEL; FEASIBILITY STUDY; HUMAN; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PREDICTION; PRIMATE; PRIORITY JOURNAL; REVIEW; STOMACH EMPTYING; SUSTAINED RELEASE FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84865796028     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.12.81     Document Type: Review

References (40)

1. Raoof A, Moriarty D, Brayden D et al. Comparison of methodologies for evaluating regional intestinal permeability. In: In Vitro-In Vivo Correlations. Young D, Devane JG, Butler J (Eds). Plenum, NY, USA (1997).
2. Fagerholm U, Lindahl A, Lennernäs H. Regional intestinal permeability differences in rats of compounds with different physicochemical properties and transport mechanisms. J. Pharm. Pharmacol. 49, 687-690 (1997). (Pubitemid 27341714)
3. Ungell A-L, Nylander S, Bergstrand S, Sjöberg Å, Lennernäs H. Membrane transport of drugs in different regions of the intestinal tract of the rat. J. Pharm. Sci. 87 360-366 (1998). (Pubitemid 28204591)
4. Berggren S, Lennernäs P, Ekelund M, Weström B, Hoogstraate J, Lennernäs H. Regional transport and metabolism of ropivacaine and its CYP3A4 metabolite PPX in human intestine. J. Pharm. Pharmacol. 55, 963-972 (2003). (Pubitemid 36916686)
5. Amidon, GL, Lennernäs, H, Shah, VP, Crison, JR. A theoretical basis for a biopharmaceutic drug classification, the correlation of in vitro drug dissolution and in vivo bioavailability. Pharm. Res. 12, 413-420 (1995).
6. Tannergren C, Bergendal A, Lennernäs H, Abrahamsson B. Toward an increasing understanding of the barriers to colonic drug absorption in humans: implications for early controlled release candidate assessment. Mol. Pharm. 6, 60-73 (2009).
7. Winkle H. Implementing quality by design. Presented at: PDA/FDA Joint Regulatory Conference. Washington, DC, USA, 24-28 September 2007.
8. US FDA. Guidance for Industry. Q8 (R2) Pharmaceutical Development. Department of Human and Human Services, Silver Spring, MD, USA (2009).
9. US FDA. Guidance for Industry Q10 Quality Systems. Department of Health and Human Services, Silver Spring, MD, USA (2009).
10. Selen A, Cruañes MT, Müllertz A et al. Meeting report. Applied biopharmaceutics and quality by design for dissolution/release specification setting: product quality for patient benefit. AAPS J. 12, 465-472. (2010).
11. Sinko PJ, Leesman GD, Amidon GL. Predicting fraction dose absorbed in humans using a mass balance approach. Pharm. Res. 8, 979-988 (1991).
12. Jamei M, Turner D, Yang J et al. Population-based mechanistic prediction of oral drug absorption. AAPS J. 11, 225-237 (2009).
13. Agoram B, Woltosz WS, Bolger MB. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv. Drug Del. Rev. 50, S41-S67 (2001). (Pubitemid 32905355)
14. Parrott N, Lavé T. Applications of physiologically based absorption models in drug discovery and development. Mol. Pharm. 5, 760-775 (2008). Good general review of physiologically based pharmacokinetic modeling applied to understanding and characterizing the oral absorption of drugs.
15. Parrott N, Lavé T. Computer models for predicting drug absorption. In: Oral Drug Absorption, Prediction and Assessment, second edition. Dressman JB, Reppas C (Eds). Informa Healthcare, NY, USA (2010). Review of computer modeling to predict and characterize oral drug absorption.
16. Poulin P, Jones R D O, Jones HM et al. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modelling approach. J. Pharm. Sci. 100, 4127-4157 (2011).
17. Rowland M, Peck C, Tucker G. Physiologically-based pharmacokinetics in drug development and regulatory science. Ann. Rev. Pharm. Tox. 51, 45-73 (2011).
18. Sugano K. Introduction to computational oral absorption simulation. Exp. Opin. Drug Metab. Toxicol. 5, 259-293 (2009).
19. Zhang X, Lionberger RA, Davit BM, Yu LX. Utility of physiologically based absorption modelling in implementing quality by design in drug development. AAPS J. 13, 59-71 (2011).
20. Bolger MB, Fraczkiewicz R, Lukacova V. Simulation of absorption, metabolism and bioavailability. In: Drug Bioavailability: Estimation of Solubility, Permeability, Absorption and Bioavailability. Methods and Principles in Medicinal Chemistry (2nd Edition). van der Waterbeemd H, Lennernäs H, Artusson P (Eds). Wiley-VCH, Weinheim, Germany (2009).
21. Lukacova V, Woltosz WS, Bolger MB. Prediction of modified release pharmacokinetics and pharmacodynamics from in vitro, immediate release and intravenous data. AAPS J. 11, 323-334. (2009).
22. Jiang W, Kim S, Zhang X et al. The role of predictive biopharmaceutical modelling and simulation in drug development and regulatory evaluation. Int. J. Pharm. 418, 151-160 (2011).
23. Watson KJ, Davis J, Jones HM. Application of physiologically based pharmacokinetic modelling to understanding the clinical pharmacokinetics of UK-369003. Drug Met. Disp. 39, 1203-1213 (2011).
24. Reddy MD, Connor A, Brennan BJ et al. Physiological modelling and assessments of regional drug bioavailability of danoprevir to determine whether a controlled release formulation is feasible. Biopharm. Drug Disp. 32, 261-275 (2011). Example that illustrates the difficulties that may be encountered in applying modeling to establish feasibility of extended release.
25. Connor A, King G, Jones K. Evaluation of human regional bioavailability to assess whether modified release development is feasible. Proc. AAPS Annual Meeting, 9(Suppl. 2), 724 (2007).
26. Zhu L, Chang I, Rubino C et al. Exposure-response analysis of an oral HIV attachment inhibitor BMS-663068 following 8 days of monotherapy in HIV-infected patients. Presented at: 12th International Workshop on Clinical Pharmacotherapy of HIV Therapy. Miami, FL, USA, 13-15 April 2011.
27. Heimbach T, Oh D-M, Li LY, Rodrúguez-Hornedo N, Garcia G, Fleisher D. Enzyme-mediated precipitation of parent drugs from their phosphate prodrugs. Int. J. Pharm. 261, 81-92 (2003). (Pubitemid 36962747)
28. Brown JR. Challenges and solutions in the delivery of a prodrug in an oral extended-release delivery system. Presented at: 9th Annual SMI conference on Controlled Release. London, UK, 28-29 March 2012.
29. Marathe P, Green D, Barbhaiya R, Wen Y, Crison JR Timmins P. Use of a pharmacokinetic absorption model and site of absorption studies to design modified release formulations for BCS3 compounds. Presented at: 3rd PharmSciFair meeting. Prague, Czech Republic, 13-17 June 2011.
30. Bergstrand M, Söderlind E, Eriksson UG, Weitschies W, Karlsson MO. A semi-mechanistic modelling strategy to link in vitro and in vivo drug release for modified release formulations. Pharm. Res. 29, 695-706 (2012).
31. Bergstrand M, Sönderlind E, Eriksson UG, Weitschies W, Karlsson MO. A semi-mechanistic modelling strategy for characterization of regional absorption properties and prospective prediction of plasma concentrations following administration of new modified release formulations. Pharm. Res. 29, 574-584 (2012).
32. Yu LX, Amidon GL. A compartmental absorption and transit model for estimating oral drug absorption. Int. J. Pharm. 186, 119-125 (1999). (Pubitemid 29459038)
33. Corrigan O. The biopharmaceutic drug classification and drugs administered in extended release (ER) formulations. In: In Vitro-In Vivo Correlations. Young D, Devane JG, Butler J (Eds). Plenum, NY, USA (1997).
34. Edwards CA. Anatomical and physiological basis: physiological factors influencing drug absorption. In: Colonic Drug Absorption and Metabolism. Marcel Dekker, NY, USA (1993).
35. Lennernäs H. Modeling gastrointestinal drug absorption requires more in vivo biopharmaceutical data: experience from in vivo dissolution and permeability studies in humans. Curr. Drug Metab. 8, 645-657 (2007). (Pubitemid 47578114)
36. Huang S-M, Rowland M. The role of physiologically based pharmacokinetic modelling in regulatory review. Clin. Pharm. Ther. 91, 542-549 (2012).
37. Jönsson S, Henningsson A, Edholm M, Salmonson T. Role of modelling and simulation: a European regulatory perspective. Clin. Pharmacokinet. 51 69-76 (2012).
38. Grillo JA, Zhao P, Bullock J et al. Utiltiy of physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice. Biopharm. Drug Dispos. 33, 99-110 (2012).
39. Lalonde RL, Kowalski KG, Hutmacher MM et al. Model-based drug development. Clin. Pharmacol. Ther. 982, 21-32 (2007). (Pubitemid 46950619)
40. Simulations Plus, Inc. GastroPlus User's Manual (Version 7.0). Lancaster, CA, USA (2010).